Marc Bos

Marc Bos

UNVERIFIED PROFILE

Are you Marc Bos?   Register this Author

Register author
Marc Bos

Marc Bos

Publications by authors named "Marc Bos"

Are you Marc Bos?   Register this Author

12Publications

892Reads

6Profile Views

Comprehensive genomic profiles of small cell lung cancer.

Nature 2015 Aug 13;524(7563):47-53. Epub 2015 Jul 13.

1] Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany. [2] Department of Pathology, University Hospital Cologne, 50937 Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14664DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861069PMC
August 2015

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

J Thorac Oncol 2015 Jul;10(7):1049-57

*Institute of Pathology, University Hospital of Cologne, Cologne, Germany; †Center for Integrated Oncology Cologne/Bonn, University Hospital of Cologne, Cologne, Germany; ‡Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; §Labor Dr. Quade und Kollegen GmbH, Cologne, Germany; ‖Institute of Human Genetics, University of Cologne, Cologne, Germany; ¶Targos Molecular Pathology GmbH, Kassel, Germany; #Department of Translational Genomics, University of Cologne, Cologne, Germany; **Cologne Center for Genomics, Cologne, Germany; ††GENterprise GENOMICS GmbH, Mainz, Germany; ‡‡Bristol-Myers Squibb R&D, Princeton, New Jersey; §§Evangelische Kliniken Johanniter, Bonn, Germany; ‖‖Malteser Krankenhaus, Lung Cancer Center, Bonn, Germany; ¶¶Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; ##Institute for Hematopathology Hamburg, Hamburg, Germany; and ***New Oncology, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000570DOI Listing
July 2015

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

J Thorac Oncol 2015 Jun;10(6):e40-3

*Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; †Center for Integrated Oncology Köln Bonn, Institute of Pathology, University Hospital of Cologne, Cologne, Germany; ‡Department of Translational Genomics, Center for Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany; §Lung Cancer Group Cologne, Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; ‖Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; ¶Center for Integrated Oncology Köln Bonn, Institute of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; and #Institute of Hematopathology Hamburg, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000503DOI Listing
June 2015

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.

Clin Cancer Res 2015 Feb 9;21(4):907-15. Epub 2014 Dec 9.

Institute of Pathology, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. Targos Molecular Pathology, Kassel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0450DOI Listing
February 2015

CD74-NRG1 fusions in lung adenocarcinoma.

Cancer Discov 2014 Apr 27;4(4):415-22. Epub 2014 Jan 27.

1Department of Translational Genomics; 2Department I of Internal Medicine; 3Laboratory of Translational Cancer Genomics; 4Network Genomic Medicine, University Hospital Cologne, Center of Integrated Oncology Cologne-Bonn; 5Center for Molecular Medicine Cologne (CMMC); 6Cologne Center for Genomics (CCG); 7Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); 8Department of Pathology, University Hospital Medical Center, University of Cologne; 9Blackfield AG; 10Max Planck Institute for Neurological Research; 11Thoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH; 12Institute of Human Genetics, Cologne; 13Computational Molecular Biology Department, Max Planck Institute for Molecular Genetics, Berlin; 14Department of Prostate Cancer Research, Institute of Pathology; 15Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn; 16Institute of Pathology; 17Department of Internal Medicine II, Jena University Hospital, Friedrich-Schiller-University, Jena; 18Institute for Pathology Bad Berka, Bad Berka, Germany;19Division of Molecular Oncology, Aichi Cancer Center Research Institute; 20Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan; Departments of 21Surgery and22Pathology, St. Vincent's Hospital; 23Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;24Department of Pathology, 25CHU Grenoble Institut National de la Santé et de la Recherche Medicale (INSERM) U823, Institute Albert Bonniot, Grenoble-Alpes University, Grenoble, France; 26Laboratory of Oncology IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo; 27Laboratory for Molecular Medicine and Biotechnology, University Campus Bio-Medico, Rome, Italy; 28Center for the Biology of Disease, VIB, Leuven; and 29Oncology Discovery, Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0633DOI Listing
April 2014

Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer.

Mod Pathol 2014 Feb 26;27(2):214-21. Epub 2013 Jul 26.

1] Institute of Pathology, University Hospital Cologne, Cologne, Germany [2] Center for Integrated Oncology Cologne/Bonn, Cologne, Germany [3] Institute of Pathology, University Hospital Göttingen, Göttingen, Germany.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/31/6/731.full.pdf
Web Search
http://www.nature.com/doifinder/10.1038/modpathol.2013.141
Publisher Site
http://dx.doi.org/10.1038/modpathol.2013.141DOI Listing
February 2014

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

Cancer Discov 2014 Feb 3;4(2):246-57. Epub 2013 Dec 3.

1Department of Translational Genomics, University of Cologne; 2Max-Planck-Institute for Neurological Research; Institutes of 3Pathology and 4Virology, University of Cologne;5Department I of Internal Medicine and Center for Integrated Oncology, University Hospital of Cologne; 6Blackfield AG, Cologne; 7Technical University Dortmund, Dortmund, Germany; 8Medical Oncology and 9Institute of Pathology, Cantonal Hospital, Luzern; 10Novartis Pharma AG, Basel, Switzerland; and 11Division of Natural Products Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0323DOI Listing
February 2014

Activated RET and ROS: two new driver mutations in lung adenocarcinoma.

Transl Lung Cancer Res 2013 Apr;2(2):112-21

Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany ; ; Center for Integrated Oncology Cologne/Bonn, Germany ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.03.08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369857PMC
April 2013